GLP1R and thyroid gland carcinoma: The study was based on more than 145 000 patients who started GLP1 receptor agonist treatment and had high statistical precision; given the upper limit of the confidence interval, the findings are incompatible with an increased relative risk of thyroid cancer of more than 31%.